Source:http://linkedlifedata.com/resource/pubmed/id/19355878
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0026809,
umls-concept:C0066117,
umls-concept:C0086418,
umls-concept:C0205373,
umls-concept:C0376358,
umls-concept:C0442120,
umls-concept:C0520484,
umls-concept:C0525635,
umls-concept:C0599894,
umls-concept:C0682323,
umls-concept:C0874159,
umls-concept:C1176299,
umls-concept:C1521840,
umls-concept:C1999216
|
| pubmed:issue |
10
|
| pubmed:dateCreated |
2009-4-9
|
| pubmed:abstractText |
An intraperitoneal (IP) monotherapy in nu/nu mice with subcutaneous xenografts of a human prostate epithelial cancer cell line:DU145 was undertaken with an aldehyde dehydrogenase 3 inhibitor MATE, that is a potent apoptogen on (DU145) in culture but not on their human prostate epithelial normal counterparts [13] . Tumour growth was slowed down but treatment had to be done 5days/week. To try to potentiate the action of MATE in vivo, a bitherapy was undertaken based on the synergetic apoptotic effect that had been observed previously in culture on DU145 treated with a methional mimic METLICO and DIMATE, an inhibitor of ALDH1 and ALDH3 [19]. The bitherapy with METLICO/MATE administered IP was as effective as the monotherapy with MATE alone by IP, but at a 2-fold lower dose of MATE and at a dose of METLICO that had no growth-inhibitory effect as a monotherapy . Hence there was definite synergism with bitherapy. To try to increase the efficacy of bitherapy, it was administered by the intra-tumoral (IT) route using the recently developed 20-bars-pressurized microinjection system from CERMA [16, 17]. IT administration of the bitherapy was indeed more effective than that by IP as regards tumour volumes are concerned. Histopathological analysis of IT-treated tumours confirmed that there were many necrotized zones but intact cells were still present. Approaches for treating a wider zone of tumour tissue by IT-bitherapy are discussed.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Aldehyde Dehydrogenase,
http://linkedlifedata.com/resource/pubmed/chemical/Aldehydes,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Morpholines,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/methional
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0929-8673
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
16
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1184-91
|
| pubmed:meshHeading |
pubmed-meshheading:19355878-Aldehyde Dehydrogenase,
pubmed-meshheading:19355878-Aldehydes,
pubmed-meshheading:19355878-Animals,
pubmed-meshheading:19355878-Biomimetics,
pubmed-meshheading:19355878-Combined Modality Therapy,
pubmed-meshheading:19355878-Drug Delivery Systems,
pubmed-meshheading:19355878-Enzyme Inhibitors,
pubmed-meshheading:19355878-Female,
pubmed-meshheading:19355878-Humans,
pubmed-meshheading:19355878-Injections, Intralesional,
pubmed-meshheading:19355878-Injections, Intraperitoneal,
pubmed-meshheading:19355878-Male,
pubmed-meshheading:19355878-Mice,
pubmed-meshheading:19355878-Mice, Nude,
pubmed-meshheading:19355878-Molecular Structure,
pubmed-meshheading:19355878-Morpholines,
pubmed-meshheading:19355878-Prostatic Neoplasms,
pubmed-meshheading:19355878-Quinazolines,
pubmed-meshheading:19355878-Tumor Burden
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Synergetic bitherapy in mice with xenografts of human prostate cancer using a methional mimic (METLICO) and an aldehyde dehydrogenase 3 inhibitor (MATE): systemic intraperitoneal (IP) and targeted intra-tumoral (IT) administration.
|
| pubmed:affiliation |
CERMA, BioPark d'Archamps, F-74160, France.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|